Thomas Greenough to Male
This is a "connection" page, showing publications Thomas Greenough has written about Male.
Connection Strength
0.071
-
Greenough TC, Straubhaar JR, Kamga L, Weiss ER, Brody RM, McManus MM, Lambrecht LK, Somasundaran M, Luzuriaga KF. A Gene Expression Signature That Correlates with CD8+ T Cell Expansion in Acute EBV Infection. J Immunol. 2015 Nov 01; 195(9):4185-97.
Score: 0.030
-
Greenough TC, Cunningham CK, Muresan P, McManus M, Persaud D, Fenton T, Barker P, Gaur A, Panicali D, Sullivan JL, Luzuriaga K. Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine. 2008 Dec 09; 26(52):6883-93.
Score: 0.019
-
Brumme ZL, Sudderuddin H, Ziemniak C, Luzuriaga K, Jones BR, Joy JB, Cunningham CK, Greenough T, Persaud D. Genetic complexity in the replication-competent latent HIV reservoir increases with untreated infection duration in infected youth. AIDS. 2019 02 01; 33(2):211-218.
Score: 0.009
-
Chancellor JR, Padmanabhan SP, Greenough TC, Sacra R, Ellison RT, Madoff LC, Droms RJ, Hinkle DM, Asdourian GK, Finberg RW, Stroher U, Uyeki TM, Cer?n OM. Uveitis and Systemic Inflammatory Markers in Convalescent Phase of Ebola Virus Disease. Emerg Infect Dis. 2016 Feb; 22(2):295-7.
Score: 0.008
-
Shiu C, Cunningham CK, Greenough T, Muresan P, Sanchez-Merino V, Carey V, Jackson JB, Ziemniak C, Fox L, Belzer M, Ray SC, Luzuriaga K, Persaud D. Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy. J Virol. 2009 Oct; 83(19):9731-42.
Score: 0.005